<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672788/" ref="ordinalpos=1198&amp;ncbi_uid=4979811&amp;link_uid=PMC3672788" image-link="/pmc/articles/PMC3672788/figure/F6/" class="imagepopup">Figure 6.  From: Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> in fibroblast-like synoviocytes. </a></div><br /><div class="p4l_captionBody"><b>Summary for the effect of calcineurin inhibitor, tacrolimus, on the regulation of RANKL expression through IL-6/sIL-6R/JAK2/STAT3/SOCS3 pathway</b>. IL-6, interleukin-6; JAK2, Janus activated kinase; RANKL, receptor activator of NF-ÎºB ligand; sIL-6R, soluble interleukin-6 receptor; SOCS3, suppressor of cytokine signaling 3; STAT3, signal transducer and activator of transcription 3.</div></div>